Cargando…
Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
Atopic dermatitis is a chronic eczematous, pruritic, inflammatory skin condition affecting children and adults. Tofacitinib is a Janus kinase inhibitor. The efficacy, safety, and pharmacokinetics of 2% tofacitinib ointment twice daily have been evaluated in a 4‐week phase 2a multisite randomized, do...
Autores principales: | Purohit, Vivek S., Ports, William C., Wang, Cunshan, Riley, Steve |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590358/ https://www.ncbi.nlm.nih.gov/pubmed/30556911 http://dx.doi.org/10.1002/jcph.1360 |
Ejemplares similares
-
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial
por: Papp, Kim A., et al.
Publicado: (2016) -
Atopic dermatitis: Tofacitinib, an option for refractory disease
por: Berbert Ferreira, Sineida, et al.
Publicado: (2020) -
Treatment of granuloma annulare with tofacitinib 2% ointment
por: Damsky, William, et al.
Publicado: (2019) -
Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
por: Peterson, Danielle M., et al.
Publicado: (2021) -
Management of treatment-resistant angiolupoid sarcoidosis with adalimumab and tofacitinib 2% ointment
por: Costanza, Marco B., et al.
Publicado: (2023)